293 related articles for article (PubMed ID: 35928283)
1. DYRK1a Inhibitor Mediated Rescue of
Zhu B; Parsons T; Stensen W; Mjøen Svendsen JS; Fugelli A; Hodge JJL
Front Pharmacol; 2022; 13():881385. PubMed ID: 35928283
[TBL] [Abstract][Full Text] [Related]
2. DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity.
Zhu B; Parsons T; Foley C; Shaw Y; Dunckley T; Hulme C; Hodge JJL
Sci Rep; 2022 Sep; 12(1):15847. PubMed ID: 36151233
[TBL] [Abstract][Full Text] [Related]
3. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
4. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
5. Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila.
Lowe SA; Usowicz MM; Hodge JJL
Neurobiol Dis; 2019 May; 125():107-114. PubMed ID: 30703437
[TBL] [Abstract][Full Text] [Related]
6. microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Chaves JCS; Machado FT; Almeida MF; Bacovsky TB; Ferrari MFR
Neurosci Lett; 2020 Jan; 714():134541. PubMed ID: 31605772
[TBL] [Abstract][Full Text] [Related]
7. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
8. Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
Wegiel J; Kaczmarski W; Barua M; Kuchna I; Nowicki K; Wang KC; Wegiel J; Yang SM; Frackowiak J; Mazur-Kolecka B; Silverman WP; Reisberg B; Monteiro I; de Leon M; Wisniewski T; Dalton A; Lai F; Hwang YW; Adayev T; Liu F; Iqbal K; Iqbal IG; Gong CX
J Neuropathol Exp Neurol; 2011 Jan; 70(1):36-50. PubMed ID: 21157379
[TBL] [Abstract][Full Text] [Related]
9. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
10. Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease.
Ryoo SR; Cho HJ; Lee HW; Jeong HK; Radnaabazar C; Kim YS; Kim MJ; Son MY; Seo H; Chung SH; Song WJ
J Neurochem; 2008 Mar; 104(5):1333-44. PubMed ID: 18005339
[TBL] [Abstract][Full Text] [Related]
11. The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Wegiel J; Dowjat K; Kaczmarski W; Kuchna I; Nowicki K; Frackowiak J; Mazur Kolecka B; Wegiel J; Silverman WP; Reisberg B; Deleon M; Wisniewski T; Gong CX; Liu F; Adayev T; Chen-Hwang MC; Hwang YW
Acta Neuropathol; 2008 Oct; 116(4):391-407. PubMed ID: 18696092
[TBL] [Abstract][Full Text] [Related]
12. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
[TBL] [Abstract][Full Text] [Related]
13. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
14. Protein phosphatase PPM1B inhibits DYRK1A kinase through dephosphorylation of pS258 and reduces toxic tau aggregation.
Lee YH; Im E; Hyun M; Park J; Chung KC
J Biol Chem; 2021; 296():100245. PubMed ID: 33380426
[TBL] [Abstract][Full Text] [Related]
15. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
[TBL] [Abstract][Full Text] [Related]
17. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
[TBL] [Abstract][Full Text] [Related]
18. DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
Becker W; Soppa U; Tejedor FJ
CNS Neurol Disord Drug Targets; 2014 Feb; 13(1):26-33. PubMed ID: 24152332
[TBL] [Abstract][Full Text] [Related]
19. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
[TBL] [Abstract][Full Text] [Related]
20. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
